首页> 美国卫生研究院文献>Scientific Reports >Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients’ Blood using Hydrogel-based Cell Block Formation
【2h】

Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients’ Blood using Hydrogel-based Cell Block Formation

机译:基于水凝胶的细胞阻滞形成从癌症患者血液中过滤的循环肿瘤细胞的细胞病理学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Circulating tumor cells have emerged as biomarkers for estimating the tumor burden and metastatic potential of cancer patients. However, to date, most of studies and applications of circulating tumor cells have been conducted and applied to epithelial cancers such as breast, colorectal, and prostate tumor. The only FDA-cleared method, CellSearch, makes use of antibody against epithelial surface protein expressed on CTCs, thus obstructing wide application for various cancers with non-epithelial and semi-epithelial characteristics including renal cell carcinoma. Due to rarity and ambiguity of CTCs, designed experiment including non-biased CTC isolation and subsequent cytopathological study for finding applicable immunomarkers are urgently needed for clinical use of CTCs for less-studied cancers. Here, in order to construct the fundamental step for CTC diagnosis without limitation of its epithelial characteristics, we present the simple and novel method which incorporate both label-free CTC isolation and pathological study using hydrogel-based cell block formation. Six cell lines from lung, ovarian, kidney cancers were used to make cell block and analyzed by conventional immunocytochemical staining method to find the candidate markers for CTC. Especially for renal cancer, the physically isolated CTCs were further immunocytochemically examined with the screened candidate markers by cell block construction, and verified their clinical utility using blood samples from patients with renal cell carcinoma. This comprehensive study demonstrates that the present approach can be used to find the potential markers for any type of cancers regardless of their epithelial characteristics and isolate the specific type of CTCs in label-free manners.
机译:循环肿瘤细胞已成为生物标志物,用于估计癌症患者的肿瘤负担和转移潜力。然而,迄今为止,已经进行了循环肿瘤细胞的大多数研究和应用,并将其应用于上皮癌,例如乳腺癌,结肠直肠癌和前列腺癌。 FDA唯一批准的方法CellSearch利用针对CTC上表达的上皮表面蛋白的抗体,从而阻碍了各种具有非上皮和半上皮特征的癌症(包括肾细胞癌)的广泛应用。由于CTC的稀有性和歧义性,对于临床研究较少的CTC,迫切需要进行设计实验,包括无偏CTC分离和随后的细胞病理学研究,以找到适用的免疫标记。在这里,为了构建CTC诊断的基本步骤而不限制其上皮特性,我们提出了一种简单新颖的方法,该方法结合了无标记CTC分离和使用基于水凝胶的细胞块形成的病理学研究。使用六种来自肺癌,卵巢癌,肾癌的细胞系进行细胞阻断,并通过常规免疫细胞化学染色方法进行分析,以找到CTC的候选标记。特别是对于肾癌,通过细胞块构建,用筛选出的候选标记物进一步对细胞分离的CTC进行了免疫细胞化学检查,并使用肾细胞癌患者的血液样本验证了其临床实用性。这项全面的研究表明,本方法可用于发现任何类型的癌症的潜在标志物,而不论其上皮特征如何,并以无标记的方式分离出特定类型的CTC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号